NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
Neurogene Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$24.17+0.92 (+3.96%)
Close on Oct 19, 2026
- Market cap
- $545.08M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$4.86 (−16.74%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Neurogene Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$87.71M.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$121.35M
TTM Q2 2026
Free cash flow
-$87.71M
TTM Q2 2026
EPS, diluted
-$5.03
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $545.08M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.51
- Dividend yield
- –
- Free cash flow yield
- -16.09%
Fundamentals
- Revenue
- $0
- Net income
- -$111.11M
- EPS, diluted
- -$5.03
- Free cash flow
- -$87.71M
- Book value per share
- $9.63
- Diluted shares
- 23M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$121.35M
Net income
-$111.11M
EPS, diluted
-$5.03
Free cash flow
-$87.71M
Reported periodTrailing twelve months